Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - May 2013


The 6th (2013) International Bio-pharmaceutical R&D Innovation Asia Summit

27 May 2013 - 29 May 2013 - Shanghai, China



Bookmark and Share


The 6th International Bio-pharmaceutical Industrial Development Innovation Forum & The 6th (2013) International Bio-pharmaceutical R&D Innovation Asia Summit will be held on May.27th-29th, 2012 in Shanghai, which organized by SEBMC, supported by International Alliance of Innovation Drug Research and European Association for Bio-industries and Biotechnology Industry Organization, at that time, more than 400 multinational pharmaceutical company leaders, global top level drug & medicine scientist and experts who from USA, Europe, China and Asia will join in this Forum, it will concern Bio-pharmaceutical, new drug research, innovative drug R&D outsourcing, pharmaceutical clinical research, translational medicine and personalized treatment technology, the Forum focus on new anticancer drugs, cardiovascular drugs, anti-diabetic drugs, neurodegenerative drugs, anti-infective drugs and resistance to major diseases drug innovation and clinical applications, antibody humanized technology and pharmaceutical technology invention, tumor molecular targeted drug development and targeted therapy technology, monoclonal antibody drug development and cell line development technology, Clinical Oncology Translational Medicine and individualized treatment, the forum will also explore that the Asian Pharmaceutical face the challenges of global blockbuster stage bio-pharmaceutical patents expiring peak, how to search for the production line of potential new drug development in Asia, how to control control the the new drug R&D investment and seek a reasonable balance during Drug Listing! Bring new drug development to maximize profits, to accelerate the transformation of drug R&D from the laboratory to clinical application, to search for future Asian new drug R&D trend and innovative model of win-win cooperation, to inject change drivers positive energy for the fast-growing Asian and emerging market R & D, to decode the Asian innovative drugs and translational medicine revolution, promote Asian new drug development and clinical medicine innovation. At the same time, The 6th (2013) International Bio-pharmaceutical and Biochemistry Instrument (Shanghai) Exhibition will be also held together, This exhibition will display comprehensively the Asian and international cutting-edge biomedical technology, the innovative biological products, laboratory equipment, clinical treatment and diagnostic testing equipment, diagnostic reagents and biochemical analysis equipment and other innovative products, this forum will be the most forefront event in Asian Pharmaceutical .



Further information
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!